Cytosorbents (CTSO) Cash from Investing Activities (2010 - 2026)
Cytosorbents' (CTSO) quarterly Cash from Investing Activities came in at $7000.0 in Q2 2026, up 105.3% on a YoY basis from $3409.6 in Q2 2025, and up 115.22% quarter-over-quarter from -$46000.0 in Q1 2026.
Powered by 
Analysis
Cytosorbents (CTSO) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Cytosorbents (CTSO) has reported Cash from Investing Activities for 17 consecutive years, with $7000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Investing Activities rose 105.3% year-over-year to $7000.0; the trailing twelve-month figure through Jun 2026 stood at -$275000.0 (up 54.32% YoY), and the FY2025 full-year result was -$415000.0, up 37.97% from the prior year.
- Cash from Investing Activities grew to $7000.0 in Q2 2026 per CTSO's latest filing, from -$46000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $140285.0 in Q2 2023 and bottomed at -$4.7 million in Q2 2022.
- Historically, Cash from Investing Activities has averaged -$473045.1 across 5 years, with a median of -$133961.0 in 2023.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities plunged 375.79% in 2022, then surged 118.39% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$206080.0 in 2022, then jumped by 34.04% to -$135922.0 in 2023, then gained by 8.77% to -$124000.0 in 2024, then sank by 134.68% to -$291000.0 in 2025, then surged by 102.41% to $7000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $7000.0, -$46000.0, and -$291000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | -26.60 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -1.62 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | -639.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | -1.96 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -193.20 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -222.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 329.80 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | 7,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Mar 31, 2026 | -46,000.00 |
| Dec 31, 2025 | -291,000.00 |
| Sep 30, 2025 | 55,000.00 |
| Jun 30, 2025 | -132,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -124,000.00 |
| Sep 30, 2024 | -299,000.00 |
| Jun 30, 2024 | -118,982.00 |
| Mar 31, 2024 | -127,018.00 |
| Dec 31, 2023 | -135,922.00 |
| Sep 30, 2023 | -257,715.00 |
| Jun 30, 2023 | 140,285.00 |
| Mar 31, 2023 | -682,884.00 |
| Dec 31, 2022 | -206,080.00 |
| Sep 30, 2022 | -716,533.00 |
| Jun 30, 2022 | -4.69 Mn |
| Mar 31, 2022 | -847,956.00 |
| Dec 31, 2021 | -1.67 Mn |
| Sep 30, 2021 | -1.02 Mn |